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Abstract
Background: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to
progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of
patients. Postoperative clearance of jaundice is one of the most important factors influencing long-term outcomes
of BA patients. Multidrug resistance protein 2 (MRP2) is one of the canalicular export pumps located in
hepatocytes; it exports organic anions and their conjugates (e.g., bilirubin) into bile canaliculus. Although MRP2 is
an essential transporter for the excretion of bilirubin, its role in the clinical course of BA patients is unclear. The
present study investigated the relationship between hepatic MRP2 expression and clinical course in BA patients,
with particular emphasis in curing jaundice after hepatoportoenterostomy.
Results: No significant differences in hepatic MRP2 expression level were observed between BA and controls
groups. There was no correlation between MRP2 expression and age at time of surgery in BA and control groups.
In BA patients, MRP2 expression level in the jaundice and jaundice-free group did not differ significantly (2.0 × 10
-4
vs 3.1 × 10
-4, p = 0.094). Although the serum level of total bilirubin just before surgery did not correlate with MRP2
expression level (rs = 0.031, p = 0.914), the serum level of total bilirubin measured at 2 weeks (rs = -0.569, p =
0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) were significantly correlated with MRP2 expression level.
Furthermore, MRP2 expression level was inversely correlated with ratio of change in serum total bilirubin level over
4 weeks (rs = -0.676, p = 0.008), which represents the serum bilirubin level measured at 4 weeks after surgery
divided by value just before surgery. There was no correlation between expression level of MRP2 and nuclear
receptors, such as retinoid × receptor a, farnesoid × receptor, pregnane × receptor, or constitutive androstane
receptor.
Conclusions: Hepatic MRP2 expression level was associated with postoperative clearance of jaundice in BA
patients, at least within 1 month after hepatoportoenterostomy. This finding suggests that not only morphological
appearance of the liver tissue but also the biological status of hepatocytes is important for BA pathophysiology.
Background
Biliary atresia (BA) is an idiopathic inflammatory oblit-
erative cholangiopathy of neonates, leading to progres-
sive biliary cirrhosis [1]. If performed within the first 3
months of life, hepatoportoenterostomy (Kasai proce-
dure) can cure jaundice in 30% to 80% of patients [2-4].
Postoperative clearance of jaundice is one of the most
important factors influencing long-term outcomes of BA
patients. A multicenter study of 104 BA patients
revealed that patients with total bilirubin level < 2 mg/
dl at 3 months after hepatoportoenterostomy had
significantly better prognoses than those with higher
bilirubin levels (native liver survival, 84% vs 16%) [5].
Studies have aimed to predict the outcome of hepato-
portoenterostomy for BA based on several variables,
such as age at surgery, microscopic analysis of the
resected specimen, and bile biochemistry [6]. Although
age at surgery is an influential variable [1], evidence
from a large series revealed that children with isolated
BA showed no statistical difference by age cohort for
clearance of jaundice or for native liver survival [1,7].
Furthermore, actual time of biliary occlusive onset
might vary between prenatal and postnatal cases. Histo-
pathological findings in the transected remnant, and in
particular the size of the biliary ductules, has been
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[6,8-10]. However, because of difficulties with consis-
tency of histological interpretation, this result can be
difficult to estimate in individual cases [1].
Recent studies of the molecular mechanisms of bile
physiology have provided a better understanding of the
pathophysiology of various cholestatic liver diseases. Dif-
ferent transporters are involved in bile secretion, and
hepatobiliary transport systems are responsible for hepa-
tic uptake and excretion of various endo- and xenobio-
tics including bile salts, bilirubin, cholesterol,
phospholipids, hormones, and drugs. Multidrug resis-
tance protein 2 (MRP2), which belongs to the ATP-
binding cassette transporter superfamily (sub-family C,
member 2: ABCC2) is one of the canalicular export
pumps located in hepatocytes; it exports organic anions
and their conjugates into bile canaliculus [11,12]. Clini-
cally, dysfunction of MRP2 is known to result in hyper-
bilirubinemia. Hereditary deficiency of MRP2, known as
Dubin-Johnson syndrome, causes hyperbilirubinemia
[13]. The risk of intrahepatic cholestasis of pregnancy is
associated with single nucleotide polymorphisms of
MRP2 [14]. Hepatic expression of MRP2 in patients
with primary sclerosing cholangitis was decreased com-
pared with non-cholestatic controls [15]. Furthermore, a
study in adult patients with biliary cancer has shown
that impaired expression of hepatic MRP2 is associated
with posthepatectomy hyperbilirubinemia [16]. Thus,
MRP2 is one of the most essential transporters for
excretion of bilirubin. However, the role of MRP2 in the
clinical course of BA patients has not been elucidated.
The present study was designed to investigate the rela-
tionship between hepatic MRP2 expression and the clin-
ical course of BA patients. In particular, the role of
MRP2 in clearance of jaundice after hepatoportoenter-
ostomy was studied. Furthermore, we assessed the asso-
ciation between expression levels of MRP2 and nuclear
transporters, which are involved in the transcriptional
regulation of MRP2.
Results
Clinical background
The clinical parameters of the three groups of patients
(BA with jaundice, BA without jaundice, and controls)
are shown in Table 1. Age at sampling of the jaundice
and jaundice-free group were (mean ± SEM) 70.6 ± 8.7
and 76.8 ± 11.4 days respectively (p = 0.619). Five of 11
BA patients underwent liver transplantation during a
follow-up of 8.5 ± 1.2 years. There was no difference of
age at sampling between those who survived without
transplantation and those who survived with transplan-
tation (p = 0.366). Native liver survival differ signifi-
cantly between the jaundice and jaundice-free groups
(p = 0.010) (Figure 1).
Hepatic expression of MRP2 and nuclear receptors
No significant difference in MRP2 expression level was
observed between BA and control patients (2.4 × 10
-4 ±
3.1 × 10
-5 vs 3.7 × 10
-4 ±6 . 0×1 0
-5, p = 0.079) (Figure
2). There was no correlation between MRP2 expression
and age at time of surgery in the BA (rs = 0.503, p =
0.067) or control group (rs = 0.514, p = 0.073). MRP2
expression levels in the jaundice and jaundice-free
group were 2.0 × 10
-4 ±2 . 9×1 0
-5 and 3.1 × 10
-4 ±6 . 2
×1 0
-5 respectively (p = 0.094) (Figure 3). There was no
difference of MRP2 expression between those who sur-
vived without transplantation and those who survived
with transplantation (p = 0.078). The levels of GAPDH
expression were not different between BA patients and
controls, between jaundice and jaundice-free group in
BA patients, and between those who survived without
transplantation and those who survived with transplan-
tation or died.
Next, the association between MRP2 expression and
the serum level of total bilirubin in the perioperative
Table 1 Clinical parameters in the jaundice, jaundice-free,
and control groups
Jaundice Jaundice-
free
Control
n=9 n=5 n=1 3
Age at sampling (days)
Serum level of total bilirubin
(mg/dl)
70.6 ± 8.7 76.8 ± 11.4 852.1 ± 101.3
Before sampling 10.7 ± 1.3 7.7 ± 2.5 0.7 ± 0.1
1 month after sampling 6.4 ± 1.0 3.1 ± 1.1 0.5 ± 0.0
3 months after
sampling
4.6 ± 1.5* 0.8 ± 0.2 0.5 ± 0.1
*Except for 3 samples, from patients that underwent hepatoportoenterostomy
followed by a secondary surgical procedure within 3 months.
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Figure 1 Native liver survival of jaundice and jaundice-free
group in BA patients. Native liver survival differ significantly
between the jaundice and jaundice-free groups (p = 0.010).
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just before surgery did not correlate with MRP2 expres-
sion level (rs = 0.031, p = 0.914). The serum level of
direct bilirubin just before surgery also had no correla-
tion (rs = -0.016, p = 0.956). The serum level of total
bilirubin measured at 2 weeks (rs = -0.569, p = 0.034)
and 4 weeks after surgery (rs = -0.620, p = 0.018) corre-
lated with MRP2 expression levels (Figure 4). The
serum level of direct bilirubin measured at 4 weeks after
surgery (rs = -0.577, p = 0.031) also correlated with
MRP2 expression levels, but that measured at 2 weeks
after the surgery did not (rs = -0.477, p = 0.085).
Furthermore, MRP2 expression levels were also inversely
correlated with ratio of change in the serum level of
total bilirubin during the 4 weeks after surgery (rs =
-0.676, p = 0.008), which represent the serum level of
bilirubin measured at 4 weeks after surgery divided by
v a l u ej u s tb e f o r es u r g e r y .T h er a t i oo fc h a n g ei nt h e
serum level of direct bilirubin during 2 weeks (rs =
-0.543, p = 0.045) and 4 weeks (rs = -0.586, p = 0.028)
also correlated with MRP2 expression levels, although
values of total bilirubin during 2 weeks did not.
T h ed a t ai nF i g u r e5s h o w sM R P 2e x p r e s s i o nl e v e lo f
BA at primary hepatoportoenterostomy and at a second-
ary surgical procedure, respectively. Although statistical
analysis could not be applied because of the small
Figure 2 Hepatic MRP2 expression level of BA patients and
controls. MRP2 expression level did not differ significantly between
the BA and control groups (2.4 × 10
-4 ± 3.1 × 10
-5 vs 3.7 × 10
-4 ±
6.0 × 10
-5, p = 0.079). Crossbars indicate median values.
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Figure 3 Hepatic MRP2 expression level of jaundice and
jaundice-free group in BA patients. MRP2 expression level did
not differ significantly between the jaundice and jaundice-free
groups (2.0 × 10
-4 ± 2.9 × 10
-5 vs 3.1 × 10
-4 ± 6.2 × 10
-5, p = 0.094).
Crossbars indicate median values.
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Figure 4 Association between hepatic MRP2 expression level
and level of total bilirubin at 4 weeks after surgery. MRP2
expression levels correlated with serum levels of total bilirubin
measured at 4 weeks after surgery (rs = -0.620, p = 0.018).
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Figure 5 Hepatic MRP2 expression level of BA patients at the
time of hepatoportoenterostomy and secondary surgical
procedure. Squares indicate patients who underwent both
hepatoportoenterostomy and a secondary surgical procedure. In
these 3 cases, MRP2 expression level at the secondary surgical
procedure increased compared with levels seen at the initial
hepatoportoenterostomy.
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Page 3 of 6number of patients, in all 3 cases that underwent 2 sur-
gical procedures, MRP2 expression level at the second-
ary procedure increased compared with levels at the
first hepatoportoenterostomy.
There was no correlation between expression level of
MRP2 and any nuclear receptor: RXRa (rs = -0.164, p >
0.05), FXR (rs = 0.373, p > 0.05), PXR (rs = 0.409, p >
0.05) and CAR (rs = 0.0257, p = 0.940).
Discussion
MRP2 is one of the canalicular export pumps located in
hepatocytes; it exports organic anions and their conju-
gates (e.g., bilirubin) into bile canaliculus [11,12]. The
effect of MRP2 is regulated at transcriptional and post-
transcriptional levels in response both to many endo-
genous and xenobiotic substances and to abnormal
states, such as biliary obstruction and inflammation
[17,18]. Biliary obstruction initiates marked changes in
transporter expression, which is reasonable for hepatic
protection [19]. Basolateral transporters for bile acid
uptake are downregulated to prevent further uptake,
and the canalicular export pump, MRP2, is also downre-
gulated. Alternatively, basolateral transport systems such
as MRP3 and 4 are compensatively upregulated to pre-
vent accumulation of potentially toxic substrates in
hepatocytes [20]. Secretion of interleukin-1b (IL-1b)
induced by obstructive cholestasis is responsible for
reduced transcription of MRP2 via decreased binding
RXRa to the MRP2 promoter [21,22]. Meanwhile,
inflammatory status induced by proinflammatory cyto-
kines, including tumor necrosis factor a,I L - 1 b, and IL-
6, also results in reduced bile flow via changing gene
expression of transporters [23,24]. MRP2 expression is
downregulated drastically in cytokinemia induced by
endotoxin administration [25-27]. In addition, MRP2
expression level in the BA liver was reported to be
downregulated compared with age-matched controls
that had non-cholestatic liver diseases [28]. In the pre-
sent study, we found no significant difference of MRP2
expression between BA and control. Our result might
be influenced by selection of controls; the average age of
controls was much older than that of BA patients. Con-
sidering the age dependency of canalicular transporters,
including MRP2 especially in small infants [17], the dif-
ference of ages might have affected the results. Further-
more, the controls include liver samples from
choledochal cyst, potentially an obstructive cholestatic
disease, although the cases of choledochal cyst that had
jaundice at the sampling were excluded in the study.
The pathophysiology of BA is characterized as inflam-
matory obliterative cholangiopathy [1]. Immunohisto-
chemical studies have revealed that activated T cells
infiltrate the periductal area with expression of various
intracellular adhesion molecules [29,30]. In the present
study, we showed that a higher hepatic MRP2 expres-
sion level at the time of surgery resulted in faster clear-
ance of jaundice with lower serum levels of bilirubin
within a month of surgery. It is still unclear what caused
difference of MRP2 expression in the BA liver. Consid-
ering the molecular mechanisms of bile physiology, pro-
longed biliary obstruction and/or advanced
inflammatory status might have effect on it, but further
studies are still necessary. Meanwhile, the level of MRP2
expression was not involved in long-term prognosis.
The discrepancy between clearance of jaundice and
prognosis could be partially explained by a small num-
ber of cases. And, prognosis of native liver of BA is also
influenced by other factors, such as liver fibrosis, portal
hypertension, and cholangitis. Regardless, MRP2 is an
important molecule in understanding the biological sta-
tus of the BA livers, and also important clinically
because sufficient clearance of jaundice is necessary for
a positive long-term prognosis.
Transcriptional regulation may result from changes in
the intracellular concentrations of bile acids and a num-
ber of lipophilic compounds that are ligands for nuclear
receptors. The key nuclear receptors influencing MRP2
expression are RXRa,F X R ,P X R ,a n dC A R[ 3 1 , 3 2 ] .W e
showed no correlation between expression level of
MRP2 and any nuclear receptor. This led us to think
that the difference of MRP2 expression level in BA
patients did not result from transcriptional changes of
nuclear receptors. Meanwhile, posttranscriptional effects
of nuclear receptors activated b yv a r i o u sa g o n i s t sh a v e
been elucidated in various animal models. Controlling
the effect of transporters via nuclear receptors may be
an approach to developing new drugs for cholestatic
liver disease [33].
In all BA patients who underwent a secondary surgical
procedure, MRP2 expression level increased after the
first operation, although jaundice worsened. All 3 cases
received ursodeoxycholic acid (UDCA) (20 mg/kg/day)
after hepatoportoenterostomy. Although the mechanism
of the anti-cholestatic effects of UDCA are not clearly
understood, UDCA-induced transcriptional upregulation
of MRP2 and insertion of transporter molecules includ-
ing MRP2 into the canalicular membrane of hepatocytes
have been reported [34]. UDCA might act to maintain
MRP2 expression during cholestasis.
Conclusions
Hepatic MRP2 expression level was associated with
postoperative clearance of jaundice in BA patients
within 1 month after hepatoportoenterostomy. This
finding suggests that not only morphological appearance
of the liver tissue but also the biological status of hepa-
tocytes is important for BA pathophysiology. It remains
unclear how MRP2 expression is regulated in the BA
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directly associated with MRP2 expression. This retro-
spective preliminary report indicates that further study
is necessary to elucidate the involvement of MRP2 in
BA pathophysiology.
Methods
Patients and tissue specimens
Fourteen liver samples from 11 patients with BA treated in
our institution from October 1998 to February 2005 were
used. Diagnosis of BA was made based on surgical find-
ings. The type of BA consisted of type 3 (n = 10) and type
1 (n = 1). There was no case with associated anomalies (e.
g., splenic malformation, situs inversus). All surgeries were
performed by 2 expert surgeons, and there were no critical
complications in the perioperative period. Eleven samples
were obtained during hepatoportoenterostomy, which was
performed at a mean age of 65.5 days (range, 21 to 128
days). Of these 11 cases, 3 cases underwent a second hepa-
toportoenterostomy, and 3 samples were taken at that
time (mean age at second surgery, 90 days; range, 64 to
114 days). The indication for the secondary procedures in
our institution is postoperative jaundice which seems to
be caused by fibrotic tissue at the hepatoportoenterost-
omy. There was no other indication, such as postoperative
bleeding or anastomotic leakage.
Serum levels of bilirubin in patients with BA were
reviewed, and BA samples were divided into two groups
on the basis of postoperative results: jaundice group (n =
9) and jaundice-free group (n = 5). “Jaundice-free” was
defined as serum levels of total bilirubin < 1.5 mg/dl
within 3 months postoperatively. Three samples from the
primary hepatoportoenterostomy followed by secondary
surgical procedures were classified into the jaundice
group. After the secondary hepatoportoenterostomy, two
of three cases had serum levels of total bilirubin < 1.5
mg/dl within 3 months after surgery, and therefore, were
classified into the jaundice-free group. The other one
case was classified into the jaundice group. A sample of a
case of type 1 BA (from primary hepatoportoenterost-
omy) was included in jaundice-free group.
Pediatric control samples were collected from 13
patients with liver diseases in the same way. They con-
sisted of patients with choledochal cysts (n = 9) and
hepatoblastoma (n = 4). The mean age of controls was
25.3 months (range, 2 to 54 months). Samples from
choledochal cysts were obtained during excision of the
cyst and hepatojejunostomy. Samples from hepatoblas-
toma included normal parts of the liver adjacent to
tumorous lesions. None of the control patients were
jaundiced at the time of sampling.
The study protocol was approved by the institutional
ethics committee of Chiba University, and informed
consent was obtained from the parents of all patients.
Quantitative reverse transcription polymerase chain
reaction
The liver samples were divided into two parts: one was
frozen immediately stored at -80°C until RNA extrac-
tion, and the second was fixed in 10% buffered formal-
dehyde solution for pathologic estimation. Total RNA
was extracted from the frozen liver using an Isogen
reagent (Nippon Gene, Tokyo, Japan). First-strand
cDNA synthesis was performed with reverse transcrip-
tase, 5 mg of total RNA, and oligo (dT) primers. Quan-
titative reverse transcription polymerase chain reaction
(qRT-PCR) was performed using the Universal ProbeLi-
brary Set and LightCycler 350S system (Roche, Man-
nheim, Germany). All cDNA samples were diluted 15-
fold as a working template in qRT-PCR. Unique probe
and gene-specific primer pair combinations for target
genes were designed using Roche ProbeFinder Software
Version 2.32. The primer sequences and probes were
follows: MRP2, 5’-AGCATGCTTCCCATGATGA-3’ and
5’-TCTAGCCGCTCTGTGGAAAC-3’ (Probe#1); glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), 5’-
AGCCACATCGCTCAGACA-3’ and 5’-GCCCAATAC-
GACCAAATCC-3’ (Probe#60); retinoid × receptor a
(RXRa), 5’-ACATGCAGATGGACAAGACG-3’ and 5’-
GAGAGCCCCTTGGAGTCAG-3’ (Probe#27); farnesoid
× receptor (FXR), 5’-TGACCTGTGAGGGGTGTAA
AG-3’ and 5’-CACTTGTACACAGCGTTTTTGG-3’
(Probe#2); pregnane × receptor (PXR), 5’-ATGCAA
GGGCTTTTTCAGG-3’ and 5’-GGGTCTTCCGGGT
GATCT-3’ (Probe#30); constitutive androstane receptor
(CAR), 5’-TAATGCGCTGACTTGTGAGG-3’ and 5’-
AGGTGGGACCAATGCTTTT-3’ (Probe#2). Briefly, 1
× Probes Master, 200 nM of each primer, 100 nM Uni-
versal ProbeLibrary probe, and 2 μl diluted cDNA tem-
plate were added to each reaction in a total volume of
20 μl. The protocol consisted of an initial denaturation
step at 95°C for 10 min, followed by 40 cycles of ampli-
fication and quantification at 95°C for 15 s, 60°C for 10
s, and 72°C for 10 s, and was finally cooled at 40°C. The
transcript amounts were estimated from the respective
standard curves and normalized to the GAPDH tran-
script amount determined in corresponding samples.
Reactions were run in duplicate.
Statistical analysis
Results are presented as mean ± SEM. Differences of mean
expression levels between groups were compared with the
student t-test or Welch’s t-test. Associations were assessed
by Pearson’s correlation coefficient test or Spearman’s
rank-correlation coefficient test, and expressed by the cor-
responding correlation coefficient (rs). Curves of native
liver survival were calculated using Kaplan-Meier metho-
dology and log rank test was used to compare survival
rates. P values < 0.05 were considered significant.
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